Saint-Herblain, France April 16, 2025 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a dynamic specialty vaccine company, has announced its active participation in the upcoming 25th World Vaccine Congress. This prestigious event is set to unfold from April 21 to April 24, 2025, at the Walter E. Washington Convention Center located in Washington, D.C. The company will be represented by a team of senior managers, led by Chief Executive Officer Thomas Lingelbach. Among the highlights will be a significant presentation focused on Valnevas IXCHIQ, the first-ever licensed chikungunya vaccine on a global scale.

Valneva will establish a presence at the congress with an exhibit booth (#424), where attendees can learn more about the company's innovative vaccine solutions and ongoing projects.

On April 22, from 11:40 AM to 12:20 PM EST, Dr. Hanneke Schuitemaker, Valneva's Chief Science Officer, will lead an interactive work group session. This session will delve into the critical issues surrounding Prophylactic Enteric Disease Vaccines and Antimicrobial Resistance, which are increasingly relevant in today's public health landscape.

Later that evening, Valneva will be present at the Vaccine Industry Excellence Awards ceremony. The company has been nominated for two prestigious accolades: the Best Biotech Award and the Best Prophylactic Vaccine Award. These nominations are in recognition of VLA15, which stands as the most advanced Lyme disease vaccine candidate currently undergoing Phase 3 clinical trials in collaboration with Pfizer.

Continuing the focus on innovation in vaccine development, on April 23 at 9:40 AM EST, Susanne Eder-Lingelbach, the Vice President of Clinical Development at Valneva, will present crucial findings regarding Valnevas chikungunya vaccine: key data in support of licensure and plans to confirm effectiveness. This presentation promises to share vital data that supports the vaccine's introduction into broader market use.

On the final day of the event, April 24 at 9:00 AM EST, Dr. Juan Carlos Jaramillo, Valnevas Chief Medical Officer, will participate in a critical panel discussion titled The Urgent Need for Vaccines Against Mosquito-Borne Diseases. He will be joined by notable experts, including Gabrielle Breugelmans from the Coalition for Epidemic Preparedness Innovations and Trevor Wellington from the Walter Reed Army Institute of Research. The discussion will be moderated by Sushant Sahastrabuddhe, Deputy Director General of the International Vaccine Institute, and aims to address the pressing need for innovative solutions to combat diseases spread by mosquitoes.

Understanding Chikungunya

The chikungunya virus (CHIKV) is a mosquito-borne pathogen transmitted primarily by the bites of infected Aedes mosquitoes. It is known to cause a range of debilitating symptoms, including fever, severe joint and muscle pain, headaches, nausea, fatigue, and rashes. Notably, the joint pain can be particularly severe, often persisting for weeks or even years after the initial infection.

Since its emergence in 2004, chikungunya has rapidly spread across the globe, resulting in extensive outbreaks in over 110 countries spanning Asia, Africa, Europe, and the Americas. Between 2013 and 2023 alone, the Americas recorded over 3.7 million cases of chikungunya, reflecting the disease's significant medical and economic burden on affected communities. Experts predict that as climate change continues to alter the habitats of mosquito vectors, the incidence of chikungunya and other mosquito-borne illnesses is likely to escalate. The World Health Organization (WHO) has consequently identified chikungunya as a substantial public health concern.

About IXCHIQ

IXCHIQ represents a groundbreaking advancement in public health as the first licensed chikungunya vaccine targeted at addressing a critical unmet medical requirement. This single-dose vaccine has been approved for use in individuals aged 12 years and older within the European Union, and for those aged 18 years and older in various regions including the United States, Canada, the United Kingdom, and Brazil. Applications to extend its use to adolescents have also been submitted in the U.S., Canada, and the U.K.

For detailed prescribing information, individuals are encouraged to refer to the official documentation approved by the relevant health authorities.

About Valneva SE

Valneva SE is at the forefront of vaccine innovation, dedicated to the development, manufacturing, and commercialization of prophylactic vaccines targeting infectious diseases with significant unmet medical needs. The company employs a specialized approach that leverages extensive expertise across various vaccine modalities to deliver first-, best-, or only-in-class vaccine solutions. With a proven track record of advancing multiple vaccines from early research and development to regulatory approval, Valneva currently markets three proprietary travel vaccines, including IXCHIQ, the worlds first chikungunya vaccine, alongside third-party vaccines.

The revenues generated from Valneva's growing commercial business play a vital role in supporting the ongoing advancement of its extensive vaccine pipeline. This pipeline includes the only Lyme disease vaccine candidate in advanced clinical development, in partnership with Pfizer, as well as leading candidates targeting Shigella, Zika virus, and other public health threats globally. More information about the company and its initiatives can be found at About Horizon Europe

Horizon Europe (#HorizonEU) stands as the European Union's flagship Research and Innovation program, operating under the long-term Multiannual Financial Framework (MFF) with a budget of 95.5 billion allocated for the period from 2021 to 2027. This initiative supports health research focused on new strategies to enhance public health, prevent diseases, and improve diagnostics and therapies, while also promoting the integration of innovative health technologies, including digital solutions.

For media and investor inquiries, please contact:

Valneva
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M: +33 (0)6 4516 7099
Email: laetitia.bachelot-fontaine@valneva.com

Joshua Drumm, Ph.D.
VP Global Investor Relations
M: +001 917 815 4520
Email: joshua.drumm@valneva.com

CEPI
Email: press@cepi.net
Phone: +44 7387 055214

Forward-Looking Statements

This press release includes forward-looking statements regarding Valneva's business operations, including potential partnerships, technological advancements, and regulatory approvals. While the actual outcomes may align with the projections made, there are inherent risks and uncertainties that may lead to substantial deviations from expected results. Potential influencing factors could range from delays in vaccine development and manufacturing to unforeseen regulatory actions and competitive pressures. Success in earlier trials does not guarantee similar results in future studies. Valneva disclaims any intention or obligation to publicly update or revise forward-looking statements as circumstances evolve.